Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Electrum Identifies New Mineralised Trends and Refines Targeting with Magnetic Survey (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Cipher Pharmaceuticals Inc
T.CPH
Alternate Symbol(s):
CPHRF
Healthcare
Biotechnology
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology...
products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:CPH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Next
(28)
•••
stockfy
X
Comment by
stockfy
on Oct 09, 2021 1:17pm
RE:RE:CPH Value
Agree. A buyout is likely because many larger names are looking for inorganic growth.
(4965)
•••
nozzpack
X
Comment by
nozzpack
on Oct 06, 2021 7:43am
RE:CPH Value
Thank you. Confirms every analyses that have been posted here. On pure fundamentals its $9 per share. Someone will take us out at $5 per share..
(99)
•••
Northforce13
X
Post by
Northforce13
on Oct 05, 2021 12:47pm
CPH Value
Cipher is unique. Did deeper research, pursant to the shocking growth in sales in Q2 + first time ever seeing product sales surpass licensing. This was/is game changing, and the market is
...more
(4965)
•••
nozzpack
X
Post by
nozzpack
on Oct 04, 2021 9:04am
Insider buying at $2.42…share buybacks
Filings by transaction date Sep 20, 2021 (filed on Sep 20, 2021) Insider Name: Wolkin, Harold Morton
...more
(4965)
•••
nozzpack
X
Comment by
nozzpack
on Sep 15, 2021 5:57pm
RE:RE:RE:RE:MOB-015
Thanks. Another sleeper not included in the current market cap..
(99)
•••
Northforce13
X
Comment by
Northforce13
on Sep 14, 2021 10:09am
RE:RE:RE:MOB-015
https://www.youtube.com/watch?v=KaMcG2ZO1Sc
(1)
•••
maxxie3
X
Comment by
maxxie3
on Sep 13, 2021 8:26pm
RE:RE:MOB-015
Would you happen to have a link. Thanks
(99)
•••
Northforce13
X
Comment by
Northforce13
on Sep 13, 2021 6:03pm
RE:MOB-015
Found all the info and answers I was looking for about MOB 015 in a video interview of the CEO
(99)
•••
Northforce13
X
Post by
Northforce13
on Sep 13, 2021 1:13pm
MOB-015
Anyone have an opinion on this? I am not knowledgable about pharma. It sounds like a product that is superior by far to what is available on the market presently. If I understand
...more
(4965)
•••
nozzpack
X
Comment by
nozzpack
on Sep 12, 2021 2:59pm
RE:Renewal of Normal Course Issuer Bid
Benefits are clearly evident in the share price gains..
(2269)
•••
Betteryear2
X
Post by
Betteryear2
on Sep 08, 2021 7:41am
Renewal of Normal Course Issuer Bid
OAKVILLE, ON, Sept. 8, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has filed, and the Toronto Stock
...more
(28)
•••
stockfy
X
Comment by
stockfy
on Aug 29, 2021 11:02am
RE:RE:Healthcare picks: After CPH, I pick Viemed (VMD)
With CPH at C$2.23, does Justin Keywood still have a job in Stifel?
(99)
•••
Northforce13
X
Post by
Northforce13
on Aug 24, 2021 10:35pm
MOB - 015, other products
Anyone in the community have any ideas as to answers on; When will MOB - 015 likely be released in the USA/Canada, have they said anything time line wise that I missed? Their annual information
...more
(4965)
•••
nozzpack
X
Post by
nozzpack
on Aug 24, 2021 8:26am
Peer Based Price to Book
The current value is 6.7 times book..see link below. Current Book value is $47 million cad. At current Price to book valuation multiupole of 6.7 , the fair market cap valuation is $315 million
...more
(4965)
•••
nozzpack
X
Post by
nozzpack
on Aug 23, 2021 8:01am
Peer Based Proxy Valuation.. $10 + CAD per share
EV = M Cap + debt - Cash =$25 m cad Ebitda = $4.1 m US x 4 X 1.25 = $20 million cad Ev to Ebitda valuation Multiple 14.40 for Biotech 14.32 for Pharm Average is 14.36 times So we have
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Mullen Group acquires company expected to generate annualized revenues of $300 million
Despite turbulent markets this logistics company continues to grow
Merger Announced to Create a Leading Yukon Copper-Gold Exploration and Development Company
New Analyst Report Lifts Almonty Target Price to CDN$5.50
Graphite One and Lucid Enter into Second Non-Binding Supply Agreement
Graphite Creek Project Approved for FAST-41 Federal Permitting Dashboard